R&D expense guidance
On its first-quarter earnings conference call, Boston Scientific (BSX) reiterated its 2019 R&D (research and development) expenses-to-sales percentage guidance of 10.5%–11%.
In the first quarter, the company reported adjusted R&D expenses of $271 million, 10.9% of the company’s total sales and close to the upper end of its first-quarter adjusted R&D-to-sales percentage guidance of 10.5%–11%. The withdrawal of surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse in the United States based on an FDA notice led to increased mesh-related accruals, which in turn pushed Boston Scientific’s R&D expenses up in the first quarter.
Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
On its first-quarter earnings conference call, Boston Scientific guided for an R&D expense ratio of 10.5%–11% for the second quarter.
Wall Street projections
Analysts expect Boston Scientific’s R&D-to-sales percentage to rise four basis points YoY to 10.75% in 2019 and then to fall 37 basis points to 10.38% in 2020 and 15 basis points to 10.23% in 2021. Analysts expect the company’s R&D-to-sales percentage to rise 14 basis points YoY to 10.58% in the second quarter but to fall 21 basis points YoY to 10.70% in the third quarter and 23 basis points YoY to 10.63% in the fourth quarter of 2019.
Royalty and tax rate guidance
On its first-quarter earnings conference call, Boston Scientific guided for a royalty rate of lower than 1% for 2019. In the first quarter, the company reported royalty expenses worth 0.6% of sales, a flat performance YoY.
On its first-quarter earnings conference call, BSX revised its 2019 adjusted tax rate from 12% to 10%. It also guided for an adjusted tax rate of close to 11% in the second quarter.